Search

Your search keyword '"Xiao, Lianchun"' showing total 861 results
Start Over Author "Xiao, Lianchun"
861 results on '"Xiao, Lianchun"'

51. MP69-11 PREDICTIVE NOMOGRAM FOR POST-NEPHROURETERECTOMY GFR ESTIMATION

Author

Hensley, Patrick, primary, Labbate, Craig, additional, Xiao, Lianchun, additional, Zganjar, Andrew, additional, Durdin, Trey, additional, Huelster, Heather, additional, Pham, Jonathan, additional, Howard, Jeffrey, additional, Pallauf, Maximilian, additional, Lombardo, Kara, additional, Potretzke, Aaron, additional, Spiess, Philippe, additional, Raman, Jay, additional, Margulis, Vitaly, additional, Singla, Nirmish, additional, Coleman, Jonathan, additional, and Matin, Surena, additional

Published
2023
Full Text
View/download PDF

52. Supplementary Table from Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy

Author

Lee, Sunyoung, primary, Shroff, Rachna T., primary, Makawita, Shalini, primary, Xiao, Lianchun, primary, Danner De Armas, Anaemy, primary, Bhosale, Priya, primary, Reddy, Kavitha, primary, Shalaby, Ahmed, primary, Raghav, Kanwal, primary, Pant, Shubham, primary, Wolff, Robert A., primary, and Javle, Milind, primary

Published
2023
Full Text
View/download PDF

53. Supplementary Figure from Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy

Author

Lee, Sunyoung, primary, Shroff, Rachna T., primary, Makawita, Shalini, primary, Xiao, Lianchun, primary, Danner De Armas, Anaemy, primary, Bhosale, Priya, primary, Reddy, Kavitha, primary, Shalaby, Ahmed, primary, Raghav, Kanwal, primary, Pant, Shubham, primary, Wolff, Robert A., primary, and Javle, Milind, primary

Published
2023
Full Text
View/download PDF

55. Supplemental Figure 1 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

56. Supplementary Figure 2 from Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA

Author

Kaseb, Ahmed O., primary, Sánchez, Nora S., primary, Sen, Shiraj, primary, Kelley, Robin K., primary, Tan, Benjamin, primary, Bocobo, Andrea G., primary, Lim, Kian H., primary, Abdel-Wahab, Reham, primary, Uemura, Marc, primary, Pestana, Roberto Carmagnani, primary, Qiao, Wei, primary, Xiao, Lianchun, primary, Morris, Jeffrey, primary, Amin, Hesham M., primary, Hassan, Manal M., primary, Rashid, Asif, primary, Banks, Kimberly C., primary, Lanman, Richard B., primary, Talasaz, AmirAli, primary, Mills-Shaw, Kenna R., primary, George, Bhawana, primary, Haque, Abedul, primary, Raghav, Kanwal P.S., primary, Wolff, Robert A., primary, Yao, James C., primary, Meric-Bernstam, Funda, primary, Ikeda, Sadakatsu, primary, and Kurzrock, Razelle, primary

Published
2023
Full Text
View/download PDF

57. Supplementary Figure 1 from Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA

Author

Kaseb, Ahmed O., primary, Sánchez, Nora S., primary, Sen, Shiraj, primary, Kelley, Robin K., primary, Tan, Benjamin, primary, Bocobo, Andrea G., primary, Lim, Kian H., primary, Abdel-Wahab, Reham, primary, Uemura, Marc, primary, Pestana, Roberto Carmagnani, primary, Qiao, Wei, primary, Xiao, Lianchun, primary, Morris, Jeffrey, primary, Amin, Hesham M., primary, Hassan, Manal M., primary, Rashid, Asif, primary, Banks, Kimberly C., primary, Lanman, Richard B., primary, Talasaz, AmirAli, primary, Mills-Shaw, Kenna R., primary, George, Bhawana, primary, Haque, Abedul, primary, Raghav, Kanwal P.S., primary, Wolff, Robert A., primary, Yao, James C., primary, Meric-Bernstam, Funda, primary, Ikeda, Sadakatsu, primary, and Kurzrock, Razelle, primary

Published
2023
Full Text
View/download PDF

58. Supplementary Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer

Author

Corn, Paul G., primary, Zhang, Miao, primary, Nogueras-Gonzalez, Graciela M., primary, Xiao, Lianchun, primary, Zurita, Amado J., primary, Subudhi, Sumit K., primary, Tu, Shi-Ming, primary, Aparicio, Ana M., primary, Coarfa, Cristian, primary, Rajapakshe, Kimal, primary, Huang, Shixia, primary, Navone, Nora M., primary, Lin, Sue-Hwa, primary, Wang, Guocan, primary, Ramachandran, Sumankalai, primary, Titus, Mark A., primary, Panaretakis, Theocharis, primary, Gallick, Gary E., primary, Efstathiou, Eleni, primary, Troncoso, Patricia, primary, and Logothetis, Christopher, primary

Published
2023
Full Text
View/download PDF

59. Supplementary Data from Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA

Author

Kaseb, Ahmed O., primary, Sánchez, Nora S., primary, Sen, Shiraj, primary, Kelley, Robin K., primary, Tan, Benjamin, primary, Bocobo, Andrea G., primary, Lim, Kian H., primary, Abdel-Wahab, Reham, primary, Uemura, Marc, primary, Pestana, Roberto Carmagnani, primary, Qiao, Wei, primary, Xiao, Lianchun, primary, Morris, Jeffrey, primary, Amin, Hesham M., primary, Hassan, Manal M., primary, Rashid, Asif, primary, Banks, Kimberly C., primary, Lanman, Richard B., primary, Talasaz, AmirAli, primary, Mills-Shaw, Kenna R., primary, George, Bhawana, primary, Haque, Abedul, primary, Raghav, Kanwal P.S., primary, Wolff, Robert A., primary, Yao, James C., primary, Meric-Bernstam, Funda, primary, Ikeda, Sadakatsu, primary, and Kurzrock, Razelle, primary

Published
2023
Full Text
View/download PDF

60. Supplemental Figure 3 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

61. Data from A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Author

Daver, Naval, primary, Boumber, Yanis, primary, Kantarjian, Hagop, primary, Ravandi, Farhad, primary, Cortes, Jorge, primary, Rytting, Michael E., primary, Kawedia, Jitesh D., primary, Basnett, Jordan, primary, Culotta, Kirk S., primary, Zeng, Zhihong, primary, Lu, Hongbo, primary, Richie, Mary Ann, primary, Garris, Rebecca, primary, Xiao, Lianchun, primary, Liu, Wenbin, primary, Baggerly, Keith A., primary, Jabbour, Elias, primary, O'Brien, Susan, primary, Burger, Jan, primary, Bendall, Linda J., primary, Thomas, Deborah, primary, and Konopleva, Marina, primary

Published
2023
Full Text
View/download PDF

62. Supplemental Figure 2 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

63. Supplemental Figure 4 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

64. Supplementary Figure 2 from A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Author

Daver, Naval, primary, Boumber, Yanis, primary, Kantarjian, Hagop, primary, Ravandi, Farhad, primary, Cortes, Jorge, primary, Rytting, Michael E., primary, Kawedia, Jitesh D., primary, Basnett, Jordan, primary, Culotta, Kirk S., primary, Zeng, Zhihong, primary, Lu, Hongbo, primary, Richie, Mary Ann, primary, Garris, Rebecca, primary, Xiao, Lianchun, primary, Liu, Wenbin, primary, Baggerly, Keith A., primary, Jabbour, Elias, primary, O'Brien, Susan, primary, Burger, Jan, primary, Bendall, Linda J., primary, Thomas, Deborah, primary, and Konopleva, Marina, primary

Published
2023
Full Text
View/download PDF

65. Supplemental Figure 5 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

66. Data from Single-Nucleotide Polymorphisms Inside MicroRNA Target Sites Influence Tumor Susceptibility

Author

Nicoloso, Milena S., primary, Sun, Hao, primary, Spizzo, Riccardo, primary, Kim, Hyunsoo, primary, Wickramasinghe, Priyankara, primary, Shimizu, Masayoshi, primary, Wojcik, Sylwia E., primary, Ferdin, Jana, primary, Kunej, Tanja, primary, Xiao, Lianchun, primary, Manoukian, Siranoush, primary, Secreto, Giorgio, primary, Ravagnani, Fernando, primary, Wang, Xuemei, primary, Radice, Paolo, primary, Croce, Carlo M., primary, Davuluri, Ramana V., primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

67. Supplementary Table 2 from Single-Nucleotide Polymorphisms Inside MicroRNA Target Sites Influence Tumor Susceptibility

Author

Nicoloso, Milena S., primary, Sun, Hao, primary, Spizzo, Riccardo, primary, Kim, Hyunsoo, primary, Wickramasinghe, Priyankara, primary, Shimizu, Masayoshi, primary, Wojcik, Sylwia E., primary, Ferdin, Jana, primary, Kunej, Tanja, primary, Xiao, Lianchun, primary, Manoukian, Siranoush, primary, Secreto, Giorgio, primary, Ravagnani, Fernando, primary, Wang, Xuemei, primary, Radice, Paolo, primary, Croce, Carlo M., primary, Davuluri, Ramana V., primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

68. Supplementary Tables 3-9 from Single-Nucleotide Polymorphisms Inside MicroRNA Target Sites Influence Tumor Susceptibility

Author

Nicoloso, Milena S., primary, Sun, Hao, primary, Spizzo, Riccardo, primary, Kim, Hyunsoo, primary, Wickramasinghe, Priyankara, primary, Shimizu, Masayoshi, primary, Wojcik, Sylwia E., primary, Ferdin, Jana, primary, Kunej, Tanja, primary, Xiao, Lianchun, primary, Manoukian, Siranoush, primary, Secreto, Giorgio, primary, Ravagnani, Fernando, primary, Wang, Xuemei, primary, Radice, Paolo, primary, Croce, Carlo M., primary, Davuluri, Ramana V., primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

69. Supplementary Table Legends 1-9, Figures 1-4, Methods from Single-Nucleotide Polymorphisms Inside MicroRNA Target Sites Influence Tumor Susceptibility

Author

Nicoloso, Milena S., primary, Sun, Hao, primary, Spizzo, Riccardo, primary, Kim, Hyunsoo, primary, Wickramasinghe, Priyankara, primary, Shimizu, Masayoshi, primary, Wojcik, Sylwia E., primary, Ferdin, Jana, primary, Kunej, Tanja, primary, Xiao, Lianchun, primary, Manoukian, Siranoush, primary, Secreto, Giorgio, primary, Ravagnani, Fernando, primary, Wang, Xuemei, primary, Radice, Paolo, primary, Croce, Carlo M., primary, Davuluri, Ramana V., primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

70. Supplementary Table 1 from Single-Nucleotide Polymorphisms Inside MicroRNA Target Sites Influence Tumor Susceptibility

Author

Nicoloso, Milena S., primary, Sun, Hao, primary, Spizzo, Riccardo, primary, Kim, Hyunsoo, primary, Wickramasinghe, Priyankara, primary, Shimizu, Masayoshi, primary, Wojcik, Sylwia E., primary, Ferdin, Jana, primary, Kunej, Tanja, primary, Xiao, Lianchun, primary, Manoukian, Siranoush, primary, Secreto, Giorgio, primary, Ravagnani, Fernando, primary, Wang, Xuemei, primary, Radice, Paolo, primary, Croce, Carlo M., primary, Davuluri, Ramana V., primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

71. Data from Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties

Author

Song, Shumei, primary, Ajani, Jaffer A., primary, Honjo, Soichiro, primary, Maru, Dipen M., primary, Chen, Qiongrong, primary, Scott, Ailing W., primary, Heallen, Todd R., primary, Xiao, Lianchun, primary, Hofstetter, Wayne L., primary, Weston, Brian, primary, Lee, Jeffrey H., primary, Wadhwa, Roopma, primary, Sudo, Kazuki, primary, Stroehlein, John R., primary, Martin, James F., primary, Hung, Mien-Chie, primary, and Johnson, Randy L., primary

Published
2023
Full Text
View/download PDF

72. Supplementary Figure 2 from Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties

Author

Song, Shumei, primary, Ajani, Jaffer A., primary, Honjo, Soichiro, primary, Maru, Dipen M., primary, Chen, Qiongrong, primary, Scott, Ailing W., primary, Heallen, Todd R., primary, Xiao, Lianchun, primary, Hofstetter, Wayne L., primary, Weston, Brian, primary, Lee, Jeffrey H., primary, Wadhwa, Roopma, primary, Sudo, Kazuki, primary, Stroehlein, John R., primary, Martin, James F., primary, Hung, Mien-Chie, primary, and Johnson, Randy L., primary

Published
2023
Full Text
View/download PDF

73. Supplementary Figure 1 from Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties

Author

Song, Shumei, primary, Ajani, Jaffer A., primary, Honjo, Soichiro, primary, Maru, Dipen M., primary, Chen, Qiongrong, primary, Scott, Ailing W., primary, Heallen, Todd R., primary, Xiao, Lianchun, primary, Hofstetter, Wayne L., primary, Weston, Brian, primary, Lee, Jeffrey H., primary, Wadhwa, Roopma, primary, Sudo, Kazuki, primary, Stroehlein, John R., primary, Martin, James F., primary, Hung, Mien-Chie, primary, and Johnson, Randy L., primary

Published
2023
Full Text
View/download PDF

74. Supplementary Figure Legends from Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties

Author

Song, Shumei, primary, Ajani, Jaffer A., primary, Honjo, Soichiro, primary, Maru, Dipen M., primary, Chen, Qiongrong, primary, Scott, Ailing W., primary, Heallen, Todd R., primary, Xiao, Lianchun, primary, Hofstetter, Wayne L., primary, Weston, Brian, primary, Lee, Jeffrey H., primary, Wadhwa, Roopma, primary, Sudo, Kazuki, primary, Stroehlein, John R., primary, Martin, James F., primary, Hung, Mien-Chie, primary, and Johnson, Randy L., primary

Published
2023
Full Text
View/download PDF

75. Supplementary Figure 3 from Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties

Author

Song, Shumei, primary, Ajani, Jaffer A., primary, Honjo, Soichiro, primary, Maru, Dipen M., primary, Chen, Qiongrong, primary, Scott, Ailing W., primary, Heallen, Todd R., primary, Xiao, Lianchun, primary, Hofstetter, Wayne L., primary, Weston, Brian, primary, Lee, Jeffrey H., primary, Wadhwa, Roopma, primary, Sudo, Kazuki, primary, Stroehlein, John R., primary, Martin, James F., primary, Hung, Mien-Chie, primary, and Johnson, Randy L., primary

Published
2023
Full Text
View/download PDF

76. Association between bariatric surgery and outcomes in chronic myeloid leukemia

Author

Haddad, Fadi G., primary, Kantarjian, Hagop M., additional, Bidikian, Aram, additional, Jabbour, Elias J., additional, Short, Nicholas J., additional, Ning, Jing, additional, Xiao, Lianchun, additional, Pemmaraju, Naveen, additional, DiNardo, Courtney D., additional, Kadia, Tapan M., additional, Marx, Kayleigh R., additional, Garcia‐Manero, Guillermo, additional, Ravandi, Farhad, additional, Sasaki, Koji, additional, and Issa, Ghayas C., additional

Published
2023
Full Text
View/download PDF

77. Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells

Author

Gu, Li, primary, Zhu, Yahui, additional, Lee, Maiya, additional, Nguyen, Albert, additional, Ryujin, Nicolas T, additional, Huang, Jian, additional, Chamseddine, Shadi, additional, Xiao, Lianchun, additional, Mohamed, Yehia I., additional, Kaseb, Ahmed O., additional, Karin, Michael, additional, and Shalapour, Shabnam, additional

Published
2023
Full Text
View/download PDF

81. Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma.

Author

Chamseddine, Shadi, Mohamed, Yehia I., Lee, Sunyoung S., Yao, James C., Hu, Zishuo Ian, Tran Cao, Hop S., Xiao, Lianchun, Sun, Ryan, Morris, Jeffrey S., Hatia, Rikita I., Hassan, Manal, Duda, Dan G., Diab, Maria, Mohamed, Amr, Nassar, Ahmed, Datar, Saumil, Amin, Hesham M., and Kaseb, Ahmed Omar

Subjects
CYTOKINES, INTERLEUKINS, ACADEMIC medical centers, CONFIDENCE intervals, LOG-rank test, CARCINOGENESIS, HOSPITAL wards, DESCRIPTIVE statistics, TUMOR markers, HEPATOCELLULAR carcinoma, OVERALL survival, ONCOLOGY
Abstract

Introduction: Circulating inflammatory cytokines play critical roles in tumor-associated inflammation and immune responses. Recent data have suggested that several interleukins (ILs) mediate carcinogenesis in hepatocellular carcinoma (HCC). However, the predictive and prognostic value of circulating ILs is yet to be validated. Our study aimed to evaluate the association of the serum ILs with overall survival (OS) and clinicopathologic features in a large cohort of HCC patients. Methods: We prospectively collected data and serum samples from 767 HCC patients treated at the University of Texas MD Anderson Cancer Center between 2001 and 2014, with a median follow-up of 67.4 months (95% confidence interval [CI]: 52.5, 83.3). Biomarker association with OS was evaluated by the log-rank method. Results: The median OS in this cohort was 14.2 months (95% CI: 12, 16.1 months). Clinicopathologic features were more advanced, and OS was significantly inferior in patients with high circulating levels of IL1-R1, IL-6, IL-8, IL-10, IL-15, IL-16, and IL-18. Conclusion: Our study shows that several serum IL levels are valid prognostic biomarker candidates and potential targets for therapy in HCC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

82. Characteristics and outcomes for patients (pts) with metastatic small cell urothelial carcinoma (mSCUC).

Author

Wilson, Nathaniel R., primary, Khandelwal, Jaanki, additional, Xiao, Lianchun, additional, Shah, Amishi Yogesh, additional, Gao, Jianjun, additional, Goswami, Sangeeta, additional, Kovitz, Craig A., additional, Guo, Charles, additional, Czerniak, Bogdan, additional, Logothetis, Christopher, additional, Corn, Paul Gettys, additional, Tannir, Nizar M., additional, Siefker-Radtke, Arlene O., additional, and Alhalabi, Omar, additional

Published
2023
Full Text
View/download PDF

84. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients

Author

Mohamed, Yehia I., primary, Duda, Dan G., additional, Awiwi, Muhammad O., additional, Lee, Sunyoung S., additional, Altameemi, Lina, additional, Xiao, Lianchun, additional, Morris, Jeffrey S., additional, Wolff, Robert A., additional, Elsayes, Khaled M., additional, Hatia, Rikita I., additional, Qayyum, Aliya, additional, Chamseddine, Shadi M., additional, Rashid, Asif, additional, Yao, James C., additional, Mahvash, Armeen, additional, Hassan, Manal M., additional, Amin, Hesham M., additional, and Kaseb, Ahmed Omar, additional

Published
2022
Full Text
View/download PDF

85. Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma

Author

Charalampakis, Nikolaos, Xiao, Lianchun, Lin, Quan, Elimova, Elena, Shimodaira, Yusuke, Harada, Kazuto, Rogers, Jane E., Mares, Jeannette, Amlashi, Fatemeh G., Minsky, Bruce D., Das, Prajnan, Hofstetter, Wayne L., Matamoros, Jr., Aurelio, Sagebiel, Tara L., Blum-Murphy, Mariela A., Lee, Jeffrey H., Weston, Brian, Bhutani, Manoop S., Mansfield, Paul F., Estrella, Jeannelyn S., Badgwell, Brian D., and Ajani, Jaffer A.

Published
2017
Full Text
View/download PDF

87. Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma

Author

Kaseb, Ahmed O., primary, Haque, Abedul, additional, Vishwamitra, Deeksha, additional, Hassan, Manal M., additional, Xiao, Lianchun, additional, George, Bhawana, additional, Sahu, Vishal, additional, Mohamed, Yehia I., additional, Carmagnani Pestana, Roberto, additional, Lombardo, Jamie Lynne, additional, Avritscher, Rony, additional, Yao, James C., additional, Wolff, Robert A., additional, Rashid, Asif, additional, Morris, Jeffrey S., additional, and Amin, Hesham M., additional

Published
2022
Full Text
View/download PDF

89. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study

Author

Shah, Amishi Y., Karam, Jose A., Malouf, Gabriel G., Rao, Priya, Lim, Zita D., Jonasch, Eric, Xiao, Lianchun, Gao, Jianjun, Vaishampayan, Ulka N., Heng, Daniel Y., Plimack, Elizabeth R., Guancial, Elizabeth A., Fung, Chunkit, Lowas, Stefanie R., Tamboli, Pheroze, Sircar, Kanishka, Matin, Surena F., Kimryn Rathmell, W., Wood, Christopher G., and Tannir, Nizar M.

Published
2017
Full Text
View/download PDF

90. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience

Author

Serpas Higbie, Victoria, primary, Rogers, Jane, additional, Hwang, Hyunsoo, additional, Qiao, Wei, additional, Xiao, Lianchun, additional, Dasari, Arvind, additional, Mola-Rudd, Kerri, additional, Morris, Van K, additional, Wolff, Robert A, additional, Raghav, Kanwal, additional, Huey, Ryan, additional, Parseghian, Christine, additional, Willis, Jason, additional, Kopetz, Scott, additional, Overman, Michael J, additional, and Johnson, Benny, additional

Published
2022
Full Text
View/download PDF

92. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable (MSS), BRAFV600E metastatic colorectal cancer.

Author

Morris, Van K., primary, Parseghian, Christine Megerdichian, additional, Escano, Michelle, additional, Johnson, Benny, additional, Raghav, Kanwal Pratap Singh, additional, Dasari, Arvind, additional, Huey, Ryan, additional, Overman, Michael J., additional, Willis, Jason, additional, Lee, Michael Sangmin, additional, Wolff, Robert A., additional, Kee, Bryan K., additional, Le, Phat, additional, Margain, Cori, additional, Gallup, Dave, additional, Tam, Alda, additional, Foo, Wai Chin, additional, Xiao, Lianchun, additional, Yun, Kyuson, additional, and Kopetz, Scott, additional

Published
2022
Full Text
View/download PDF

95. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma:a randomised, open-label, phase 2 trial

Author

Kaseb, Ahmed Omar, Hasanov, Elshad, Cao, Hop Sanderson Tran, Xiao, Lianchun, Vauthey, Jean Nicolas, Lee, Sunyoung S., Yavuz, Betul Gok, Mohamed, Yehia I., Qayyum, Aliya, Jindal, Sonali, Duan, Fei, Basu, Sreyashi, Yadav, Shalini S., Nicholas, Courtney, Sun, Jing Jing, Singh Raghav, Kanwal Pratap, Rashid, Asif, Carter, Kristen, Chun, Yun Shin, Tzeng, Ching Wei David, Sakamuri, Divya, Xu, Li, Sun, Ryan, Cristini, Vittorio, Beretta, Laura, Yao, James C., Wolff, Robert A., Allison, James Patrick, Sharma, Padmanee, Kaseb, Ahmed Omar, Hasanov, Elshad, Cao, Hop Sanderson Tran, Xiao, Lianchun, Vauthey, Jean Nicolas, Lee, Sunyoung S., Yavuz, Betul Gok, Mohamed, Yehia I., Qayyum, Aliya, Jindal, Sonali, Duan, Fei, Basu, Sreyashi, Yadav, Shalini S., Nicholas, Courtney, Sun, Jing Jing, Singh Raghav, Kanwal Pratap, Rashid, Asif, Carter, Kristen, Chun, Yun Shin, Tzeng, Ching Wei David, Sakamuri, Divya, Xu, Li, Sun, Ryan, Cristini, Vittorio, Beretta, Laura, Yao, James C., Wolff, Robert A., Allison, James Patrick, and Sharma, Padmanee

Abstract

Background: Hepatocellular carcinoma has high recurrence rates after surgery; however, there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy has been shown to improve survival in advanced hepatocellular carcinoma; we therefore aimed to evaluate the safety and tolerability of perioperative immunotherapy in resectable hepatocellular carcinoma. Methods: In this single-centre, randomised, open-label, phase 2 trial, patients with resectable hepatocellular carcinoma were randomly assigned (1:1) to receive 240 mg of nivolumab intravenously every 2 weeks (for up to three doses before surgery at 6 weeks) followed in the adjuvant phase by 480 mg of nivolumab intravenously every 4 weeks for 2 years, or 240 mg of nivolumab intravenously every 2 weeks (for up to three doses before surgery) plus one dose of 1 mg/kg of ipilimumab intravenously concurrently with the first preoperative dose of nivolumab, followed in the adjuvant phase by 480 mg of nivolumab intravenously every 4 weeks for up to 2 years plus 1 mg/kg of ipilimumab intravenously every 6 weeks for up to four cycles. Patients were randomly assigned to the treatment groups by use of block randomisation with a random block size. The primary endpoint was the safety and tolerability of nivolumab with or without ipilimumab. Secondary endpoints were the proportion of patients with an overall response, time to progression, and progression-free survival. This trial is registered with ClinicalTrials.gov (NCT03222076) and is completed. Findings: Between Oct 30, 2017, and Dec 3, 2019, 30 patients were enrolled and 27 were randomly assigned: 13 to nivolumab and 14 to nivolumab plus ipilimumab. Grade 3–4 adverse events were higher with nivolumab plus ipilimumab (six [43%] of 14 patients) than with nivolumab alone (three [23%] of 13). The most common treatment-related adverse events of any grade were increased alanine aminotransferase (three [23%] of 13 patients on nivolumab vs seven [50%] of 14 pa

Published
2022

99. Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia

Author

DiNardo, Courtney D., primary, Lachowiez, Curtis A., additional, Takahashi, Koichi, additional, Loghavi, Sanam, additional, Kadia, Tapan, additional, Daver, Naval, additional, Xiao, Lianchun, additional, Adeoti, Maria, additional, Short, Nicholas J., additional, Sasaki, Koji, additional, Wang, Sa A., additional, Borthakur, Gautam, additional, Issa, Ghayas, additional, Maiti, Abhishek, additional, Alvarado, Yesid, additional, Pemmaraju, Naveen, additional, Bravo, Guillermo Montalban, additional, Masarova, Lucia, additional, Yilmaz, Musa, additional, Jain, Nitin, additional, Andreeff, Michael, additional, Garcia‐Manero, Guillermo, additional, Kornblau, Steven, additional, Ravandi, Farhad, additional, Jabbour, Elias, additional, Konopleva, Marina Y., additional, and Kantarjian, Hagop M., additional

Published
2022
Full Text
View/download PDF

100. LBA01-10 INTERIM RESULTS FROM A PHASE 1B CLINICAL TRIAL EVALUATING TOLERABILITY AND ACTIVITY OF FGFR INHIBITION IN LOCALIZED UPPER TRACT UROTHELIAL CARCINOMA (UTUC)

Author

Matin, Surena, primary, Adibi, Mehrad, additional, Shah, Amishi, additional, Alhalabi, Omar, additional, Corn, Paul, additional, Guo, Charles, additional, Amirtharaj, Rhenita, additional, Lozano, Marisa, additional, Xiao, Lianchun, additional, Pal, Sumanta, additional, and Campbell, Matthew, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results